Clinical Trial Search

Primary: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Dose Limiting Toxicities (DLTs) — 4; 5; 19; 36 Participants

Primary: Change in Hypoxic Burden (HB) Log Transformed - Log10HB[(%*Min)/h] — -0.40; -0.21; 0.18 difference in log10HB[(%*min)/h]

Primary: Number of Participants Completing Genetic Testing — 22; 15; 31; 39 Participants — p=0.14

Primary: Mean Absolute Relative Difference Between CGM Value and Capillary Blood Glucose (Self-monitoring Blood Glucose [SMBG]) — 13.8 percent difference

Primary: Number of Participants With All Adverse Events (AEs), Medically Attended Adverse Events (MAAEs), Serious Adverse Events (SAEs), and Significant New Medical Conditions…

Primary: Plasma Viscosity — 2.35; 2.47; 1.61; 2.47 cP

Primary: Percentage of Participants Achieving Clinical Remission — 24.8; 15.2 Percentage of participants — p==0.026

Primary: Treatment-specific Baseline Estimated Glomerular Filtration Rate Based on Creatinine (eGFRcr) — 32.7; 34.9 mL/min/1.73m^2

Primary: Number of Patients Where TraceIT Tissue Marker Placement Achieved — 6 Participants

Primary: Prepulse Inhibition (PPI) — 32.45; 26.85; 14.11; 11.78 % inhibition of startle

Primary: Total Opioid Consumption During the First 72 Hours Postoperatively as Measured in Morphine Equivalents (mg) — 208; 203; 202 mg morphine equivalents

Primary: Working Memory Capacity Composite Score — .64; .70; .64; .72 Proportion of correct responses — p== .69

Primary: Choices to Smoke — 26.15; 30; 38.33 Percentage of Total Choices

Primary: Accuracy of Sensor by Arms Calculation — 1.62; 1.56; 1.48; 1.72 Root Mean Square Error (%)

Primary: Number of Participants With Unsafe Swallowing — 7; 1; 3; 0 Participants